Day: April 2, 2024

Expect Topline Data for Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab for Alzheimer’s Disease in Q3 2024 Company raised $17.9 million of new financing during Q4 2023 and Q1 2024 ROCHESTER, N.Y., April 02, 2024 (GLOBE NEWSWIRE) — Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the fourth quarter ended December 31, 2023 and provided a corporate update on key programs. Vaccinex achieved several important clinical milestones for pepinemab in both Alzheimer’s disease and Head and Neck Cancer. Alzheimer’s Disease (AD):In June 2024, anticipate completing planned 12-months treatment of patients with mild Alzheimer’s disease in the randomized, double-blind,...

SARASOTA, Fla., April 02, 2024 (GLOBE NEWSWIRE) — Roper Technologies, Inc. (Nasdaq: ROP) announced that its financial results for the first quarter of 2024, ended March 31, 2024, will be released before the market opens on Friday, April 26, 2024. A conference call to discuss these results has been scheduled for 8:00 AM ET on Friday, April 26, 2024. The call can be accessed via webcast or by dialing +1 800-836-8184 (US/Canada) or +1 646-357-8785, using confirmation number 02972. Webcast information and conference call materials will be made available in the Investors section of Roper’s website prior to the start of the call. About Roper Technologies Roper Technologies is a constituent of the Nasdaq 100, S&P 500, and Fortune 1000. Roper has a proven, long-term track record of compounding cash flow and shareholder value. The...

Collaboration targets rapidly growing European e-bicycle market, which analysts expect will surpass $8.1 billion by 2030 WUXI, China, April 02, 2024 (GLOBE NEWSWIRE) — LOBO EV Technologies Ltd. (Nasdaq: LOBO) (“LOBO” or the “Company”), an innovative electric vehicle manufacturer and seller, today announced its new strategic collaboration with Serbian distributor CSM2017 Doo (“CSM2017”), marking a milestone in its expansion into the burgeoning electric vehicle market in Eastern Europe. With a growing demand for sustainable transportation options, the region presents a ripe opportunity for LOBO EV’s innovative product lineup, starting with the CSM-01 e-bicycle. “Our collaboration with CSM2017 marks a pivotal step in LOBO’s journey towards global expansion and accelerating growth,” stated Huajian Xu, CEO of LOBO EV. “Working...

ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended December 31, 2023, and reported on recent corporate developments. Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., commented, “In 2023, we made significant strides in advancing the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet designed for treating opioid use disorder (OUD). The Phase I trial yielded positive safety and pharmacokinetic (PK) results, indicating that BICX104 was generally well-tolerated with no serious adverse events. Subjects experienced therapeutic levels of naltrexone for an average of 84 days, aligning with...

Saint Simons Island, GA, April 02, 2024 (GLOBE NEWSWIRE) — DEEP GREEN Waste & Recycling Inc. (OTC: DGWR) is pleased to release the following letter to shareholders which provides details on its recent performance highlights, service offerings and growth strategy going forward. Dear Shareholder,  I am pleased to share with you the latest developments and achievements of DEEP GREEN Waste & Recycling Inc. over the past two months. First and foremost, I would like to highlight the successful completion of a $2 million asbestos removal project at Vanderbilt University Medical Center in Nashville by our subsidiary, Lyell Environmental Services, Inc. (LES). This project not only represents the largest single abatement project in the history of DEEP GREEN but also demonstrates our commitment to environmental stewardship and positions...

TAMPA, Fla., April 02, 2024 (GLOBE NEWSWIRE) — Kforce Inc. (NASDAQ: KFRC), a provider of professional staffing services and solutions, will release first quarter results post-market on Monday, April 29, 2024, followed by a conference call at 5:00 pm ET to discuss the results. The dial-in number is (888) 550-5417 and the conference passcode is “Kforce”. A replay of the call will be available on our website at https://investor.kforce.com for one year after the call. About Kforce Inc. Kforce is a solutions firm specializing in technology and other professional staffing services. Each year, we provide career opportunities for over 20,000 highly skilled professionals on a temporary, consulting, or direct-hire basis. These professionals work with approximately 2,500 clients, including a significant majority of the Fortune 500, helping...

PURCHASE, N.Y., April 02, 2024 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced today that the Company’s president and CEO, Lisa Ricciardi, will present at the 23rd Annual Needham Virtual Healthcare Conference taking place April 8-11, 2024. During her presentation, Ms. Ricciardi will review recent corporate accomplishments and anticipated clinical milestones. Details of Cognition’s presentation are as follows: Event: Annual Needham Virtual Healthcare Conference Date/Time: Thursday, April 11, 2024 at 8:00 a.m. Eastern TimeWebcast: https://wsw.com/webcast/needham138/cgtx/2268084 A live webcast of the presentation will be available on the “events and presentations” section of Cognition’s investor...

Australia Strategically Selected as Beachhead for Commercial Expansion of Else Products Across the Asia Pacific Region Amazon First to Carry Else’s New ‘Follow-On’ Formula (6-12m) for Infants and ‘Toddler Drink’ (12-36m) in AustraliaVANCOUVER, British Columbia, April 02, 2024 (GLOBE NEWSWIRE) — ELSE NUTRITION HOLDINGS INC. (BABY) (BABYF) (0YL.F) (“Else” or the “Company”) is proud to announce the official commercial launch of its first-in-class ‘Follow-On’ formula for infants ages 6-12 months in Australia. The commercial launch of the Follow-On formula for infants in Australia is a significant milestone as it marks the first country, along with New Zealand, in which the Company’s new infant formula is eligible for sale. In addition, the Company announces the launch of its Toddler Drink for toddlers ages 12-36 months in Australia. The...